Jazz Pharmaceuticals Begins Enrollment For Clinical Trial To Evaluate JZP150 For Adults With PTSD
Biopharmaceutical company Jazz Pharmaceuticals plc (NASDAQ: JAZZ) announced Thursday that it has enrolled the first patient in its Phase 2 clinical trial evaluating the safety and efficacy of JZP150, an investigational first-in-class small molecule for the treatment of adults with p
